We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
Read MoreHide Full Article
Key Takeaways
Immunovant rose 10.8% on six-month off-treatment results for batoclimab in Graves' disease.
About 80% of patients maintained normalized thyroid hormone levels during follow-up.
IMVT aims to use these results to accelerate the development of lead candidate IMVT-1402 in GD.
Immunovant, Inc. (IMVT - Free Report) shares gained 10.8% on Wednesday after the company announced new six-month off-treatment results from a proof-of-concept study evaluating its investigational candidate, batoclimab, in patients with uncontrolled Graves’ disease (GD). Batoclimab is a fully human monoclonal antibody targeting FcRn.
The proof-of-concept study evaluated Immunovant’s batoclimab in patients with active GD who continued to show elevated thyroid hormone levels (hyperthyroidism) despite antithyroid drug (ATD) therapy. In the first 24 weeks of the study, patients were treated with the candidate, who then entered a 24-week off-treatment follow-up period. The primary endpoint was normalization or reduction of thyroid hormone levels (free T3 and T4) without increasing baseline ATD dosage at week 24.
IMVT’s GD Study Data of Batoclimab in Detail
Data readout from Immunovant’s proof-of-concept study showed sustained benefits during the off-treatment period. Of the 21 patients who entered the off-treatment period, approximately 80% (17/21) maintained normalized thyroid hormone levels (T3/T4) throughout the follow-up period, demonstrating strong durability of response over six months.
Year to date, Immunovant shares have plunged 32.6% against the industry’s 3.5% growth.
Image Source: Zacks Investment Research
Among the responders, roughly half (8/17) achieved ATD-free remission, while an additional 30% (5/17) required only minimal ATD doses of 2.5 mg/day. In the proof-of-concept study, batoclimab was well-tolerated and demonstrated an acceptable safety profile, consistent with previous studies of the candidate.
The reported data, which will be presented at an upcoming medical conference, suggest that FcRn blockade may offer a promising therapeutic approach for GD. Per IMVT, the findings demonstrate a potential for disease modification, as several patients achieved durable remission even after treatment withdrawal. If approved by the FDA, batoclimab could represent a significant advance in addressing unmet needs in GD treatment, where current treatment options are limited and not as effective.
IMVT’s GD Program for Lead Candidate IMVT-1402
Immunovant is looking to leverage the batoclimab data for GD to expedite the development of its lead candidate, IMVT-1402, for the same indication. IMVT-1402 is a novel, fully-human monoclonal antibody that selectively binds to and inhibits FcRn.
Immunovant has already initiated two potentially registrational global studies of IMVT-1402 for GD. Both studies are designed to evaluate a 600 mg dose of the candidate for up to 52 weeks. The studies are currently enrolling patients worldwide, with top-line results anticipated in 2027.
In the past 60 days, estimates for CorMedix’s earnings per share have increased from $1.10 to $1.49 for 2025. During the same time, earnings per share estimates for 2026 have increased from $1.46 to $2.16. Year to date, shares of CRMD have surged 69.1%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 34.85%.
In the past 60 days, estimates for Pharming Group’s 2025 loss per share have narrowed from 40 cents to 10 cents. For 2026, the estimate for PHAR’s earnings per share has improved from 7 cents to 27 cents. PHAR stock has rallied 42.7% year to date.
Pharming Group’s earnings beat estimates in two of the trailing four reported quarters and missed on the remaining two occasions, delivering an average negative surprise of 39.14%.
In the past 60 days, estimates for Kiniksa Pharmaceuticals’ 2025 earnings per share have increased from 74 cents to $1.03. Earnings per share estimates for 2026 have increased from $1.19 to $1.60 during the same period. KNSA stock has surged 79.4% year to date.
Kiniksa Pharmaceuticals’ earnings beat estimates in two of the trailing four reported quarters and missed on the remaining two occasions, delivering an average negative surprise of 330.56%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
Key Takeaways
Immunovant, Inc. (IMVT - Free Report) shares gained 10.8% on Wednesday after the company announced new six-month off-treatment results from a proof-of-concept study evaluating its investigational candidate, batoclimab, in patients with uncontrolled Graves’ disease (GD). Batoclimab is a fully human monoclonal antibody targeting FcRn.
The proof-of-concept study evaluated Immunovant’s batoclimab in patients with active GD who continued to show elevated thyroid hormone levels (hyperthyroidism) despite antithyroid drug (ATD) therapy. In the first 24 weeks of the study, patients were treated with the candidate, who then entered a 24-week off-treatment follow-up period. The primary endpoint was normalization or reduction of thyroid hormone levels (free T3 and T4) without increasing baseline ATD dosage at week 24.
IMVT’s GD Study Data of Batoclimab in Detail
Data readout from Immunovant’s proof-of-concept study showed sustained benefits during the off-treatment period. Of the 21 patients who entered the off-treatment period, approximately 80% (17/21) maintained normalized thyroid hormone levels (T3/T4) throughout the follow-up period, demonstrating strong durability of response over six months.
Year to date, Immunovant shares have plunged 32.6% against the industry’s 3.5% growth.
Image Source: Zacks Investment Research
Among the responders, roughly half (8/17) achieved ATD-free remission, while an additional 30% (5/17) required only minimal ATD doses of 2.5 mg/day. In the proof-of-concept study, batoclimab was well-tolerated and demonstrated an acceptable safety profile, consistent with previous studies of the candidate.
The reported data, which will be presented at an upcoming medical conference, suggest that FcRn blockade may offer a promising therapeutic approach for GD. Per IMVT, the findings demonstrate a potential for disease modification, as several patients achieved durable remission even after treatment withdrawal. If approved by the FDA, batoclimab could represent a significant advance in addressing unmet needs in GD treatment, where current treatment options are limited and not as effective.
IMVT’s GD Program for Lead Candidate IMVT-1402
Immunovant is looking to leverage the batoclimab data for GD to expedite the development of its lead candidate, IMVT-1402, for the same indication. IMVT-1402 is a novel, fully-human monoclonal antibody that selectively binds to and inhibits FcRn.
Immunovant has already initiated two potentially registrational global studies of IMVT-1402 for GD. Both studies are designed to evaluate a 600 mg dose of the candidate for up to 52 weeks. The studies are currently enrolling patients worldwide, with top-line results anticipated in 2027.
Immunovant, Inc. Price and Consensus
Immunovant, Inc. price-consensus-chart | Immunovant, Inc. Quote
IMVT’s Zacks Rank and Stocks to Consider
Immunovant currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are CorMedix (CRMD - Free Report) , Pharming Group (PHAR - Free Report) and Kiniksa Pharmaceuticals (KNSA - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for CorMedix’s earnings per share have increased from $1.10 to $1.49 for 2025. During the same time, earnings per share estimates for 2026 have increased from $1.46 to $2.16. Year to date, shares of CRMD have surged 69.1%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 34.85%.
In the past 60 days, estimates for Pharming Group’s 2025 loss per share have narrowed from 40 cents to 10 cents. For 2026, the estimate for PHAR’s earnings per share has improved from 7 cents to 27 cents. PHAR stock has rallied 42.7% year to date.
Pharming Group’s earnings beat estimates in two of the trailing four reported quarters and missed on the remaining two occasions, delivering an average negative surprise of 39.14%.
In the past 60 days, estimates for Kiniksa Pharmaceuticals’ 2025 earnings per share have increased from 74 cents to $1.03. Earnings per share estimates for 2026 have increased from $1.19 to $1.60 during the same period. KNSA stock has surged 79.4% year to date.
Kiniksa Pharmaceuticals’ earnings beat estimates in two of the trailing four reported quarters and missed on the remaining two occasions, delivering an average negative surprise of 330.56%.